Clinical trial
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
NCT00024284 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00024284 |
|---|---|
| Title | Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors |
| Official title | A Phase I Study Of Carboplatin And Irinotecan In Patients 1-21 Years Of Age With Refractory Solid Tumors |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Childhood Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | carboplatin, irinotecan hydrochloride |
| Start date | Jun 1, 2001 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 5, 2013 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: